Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-19 4:45 pm Purchase | 2025-12-12 | 13G | iBio, Inc. IBIO | Logos Global Management LP | 2,000,000 8.900% | 2,000,000 (New Position) | Filing History |
| 2025-11-18 5:57 pm Sale | 2025-11-14 | 13D | Design Therapeutics, Inc. DSGN | Logos Global Management LP | 2,515,000 4.400% | -740,000 (-22.73%) | Filing History |
| 2025-11-14 3:04 pm Purchase | 2025-11-06 | 13G | Palatin Technologies, Inc. PTN | Logos Global Management LP | 142,292 9.900% | 142,292 (New Position) | Filing History |
| 2025-11-14 1:01 pm Sale | 2025-09-30 | 13G | Verastem, Inc. VSTM | Logos Global Management LP | 3,175,000 4.800% | -250,000 (-7.30%) | Filing History |
| 2025-11-14 12:59 pm Sale | 2025-09-30 | 13G | Erasca, Inc. ERAS | Logos Global Management LP | 13,600,000 4.800% | -1,500,000 (-9.93%) | Filing History |
| 2025-11-12 5:10 pm Sale | 2025-11-07 | 13D | Design Therapeutics, Inc. DSGN | Logos Global Management LP | 3,255,000 5.700% | -977,627 (-23.10%) | Filing History |
| 2025-10-15 5:18 pm Sale | 2025-10-13 | 13D | Arvinas, Inc. ARVN | Logos Global Management LP | 2,500,000 3.400% | -3,800,000 (-60.32%) | Filing History |
| 2025-08-22 4:44 pm Purchase | 2025-08-15 | 13D | Arvinas, Inc. ARVN | Logos Global Management LP | 6,300,000 8.600% | 1,500,000 (+31.25%) | Filing History |
| 2025-08-14 4:56 pm Purchase | 2025-06-30 | 13G | Erasca, Inc. ERAS | Logos Global Management LP | 15,100,000 5.300% | 15,100,000 (New Position) | Filing History |
| 2025-08-14 2:24 pm Purchase | 2025-06-30 | 13G | Crescent Biopharma, Inc. CBIO | Logos Global Management LP | 575,000 4.100% | 575,000 (New Position) | Filing History |
| 2025-08-14 1:16 pm Sale | 2025-06-30 | 13G | Prothena Corporation plc PRTA | Logos Global Management LP | 0 0.000% | -2,950,000 (Position Closed) | Filing History |
| 2025-08-14 1:14 pm Sale | 2025-06-30 | 13G | Annexon, Inc. ANNX | Logos Global Management LP | 0 0.000% | -6,600,000 (Position Closed) | Filing History |
| 2025-07-28 7:39 pm Purchase | 2025-07-21 | 13G | Verastem, Inc. VSTM | Logos Global Management LP | 3,425,000 6.200% | 3,425,000 (New Position) | Filing History |
| 2025-06-16 6:10 pm Purchase | 2025-06-09 | 13D | Arvinas, Inc. ARVN | Logos Global Management LP | 4,800,000 6.400% | 4,800,000 (New Position) | Filing History |
| 2025-06-04 5:18 pm Purchase | 2025-05-29 | 13G | Prothena Corporation plc PRTA | Logos Global Management LP | 2,950,000 5.500% | 2,950,000 (New Position) | Filing History |
| 2025-05-13 7:29 pm Purchase | 2025-03-18 | 13D | Olema Pharmaceuticals, Inc. OLMA | Logos Global Management LP | 3,208,875 4.700% | 3,208,875 (New Position) | Filing History |
| 2025-04-28 7:15 pm Purchase | 2025-04-21 | 13G | Annexon, Inc. ANNX | Logos Global Management LP | 6,600,000 6.000% | 3,700,000 (+127.59%) | Filing History |
| 2025-02-14 1:40 pm Sale | 2024-12-31 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 0 0.000% | -208,333 (Position Closed) | Filing History |
| 2025-02-14 1:34 pm Sale | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | Logos Global Management LP | 0 0.000% | -3,500,000 (Position Closed) | Filing History |
| 2024-11-27 2:22 pm Purchase | 2024-11-25 | 13G | GlycoMimetics, Inc. GLYC | Logos Global Management LP | 50,000 7.800% | 50,000 (New Position) | Filing History |